

## Authorizations granted by the Shareholders' Meeting to the Board of Directors to increase share capital

 $The following \ table \ summarizes \ authorizations \ still \ in \ effect \ and \ those \ that \ have \ expired \ since \ the \ last \ Shareholders' \ Meeting.$ 

|    | rpose of the<br>thorization   | Maximum<br>amount (1) (2)<br>(in euros)  | Authorization<br>date and<br>resolution<br>number | Expiry<br>date | Used during 2021   |
|----|---|--|---|----------------|--|
| a) | Purchase by the Company<br>of its own shares under a<br>share buyback program <sup>(3)</sup>  | 10% of the share capital   | 05/20/2021 (16 <sup>th</sup> )                    | 11/20/2022     | 1,064,097 shares were purchased under<br>the share buyback program (excluding<br>the liquidity contract) at an average price<br>of €187.95   |
|    |   |  |   |                | As part of the liquidity contract:   |
|    |   |  |   |                | <ul> <li>a) 390,487 shares purchased at an average price of €154.32</li> <li>b) 407,487 shares sold at an average price of €156.80</li> <li>c) At December 31, 2021, the liquidity account balance comprises 3,964 shares and approximately €28 million in cash and monetary UCITS.</li> </ul> |
| b) | Cancellation of treasury shares   | 10% of share<br>capital per<br>24-month period   | 05/20/2020 (22 <sup>nd</sup> )                    | 07/20/2022     | This authorization was not used in 2021  |
| c) | Share capital increase by capitalizing additional paid-in capital, reserves, profit or other eligible amounts   | €1.5 billion<br>(par value)  | 05/20/2020 (23 <sup>rd</sup> )                    | 07/20/2022     | This authorization was not used in 2021  |
| d) | Share capital increase by issuing shares and/or securities granting access to the share capital, or granting a right to allocation of debt instruments, with retention of PSR (Pre-emptive Subscription Rights)                   | €540 million<br>(par value)<br>€9.3 billion<br>(issue amount)  | 05/20/2020 (24 <sup>th</sup> )                    | 07/20/2022     | This authorization was not used in 2021  |
| e) | Share capital increase by issuing shares and/or securities granting access to the share capital, or granting a right to allocation of debt instruments, with cancellation of PSR, by public offering other than private placement | €135 million<br>(par value)<br>€3.1 billion<br>(issue amount)  | 05/20/2020 (25 <sup>th</sup> )                    | 07/20/2022     | This authorization was not used in 2021  |
| f) | Share capital increase by issuing shares and/or securities granting access to the share capital, or granting a right to allocation of debt instruments, with cancellation of PSR, by private placement                            | €135 million<br>(par value)<br>€3.1 billion<br>(issue amount)  | 05/20/2020 (26 <sup>th</sup> )                    | 07/20/2022     | This authorization was not used in 2021  |
| g) | Setting the issue price of shares in the context of a share capital increase with cancellation of PSR   | €135 million<br>(par value)<br>€3.1 billion (issue<br>amount) 10% of<br>share capital per<br>12-month period | 05/20/2020 (27 <sup>th</sup> )                    | 07/20/2022     | This authorization was not used in 2021  |

| V. |  |
|----|--|

| Purpose of the authorization |   | Maximum<br>amount (1) (2)<br>(in euros)  | Authorization<br>date and<br>resolution<br>number | Expiry<br>date | Used during 2021   |
|------------------------------|---|--|---|----------------|--|
| h)                           | Increase in the number of shares to be issued in case of a share capital increase in the context of resolutions (d) to (f) ( <i>Greenshoe</i> ) with and without PSR                | Within the limit<br>of the ceiling<br>applicable to the<br>initial increase              | 05/20/2020 (28 <sup>th</sup> )                    | 07/20/2022     | This authorization was not used in 2021  |
| i)                           | Share capital increase by issuing shares and/ or securities granting access to the share capital in consideration for contributions in kind   | €135 million<br>(par value)<br>€3.1 billion<br>(issue amount)<br>10% of share<br>capital | 05/20/2020 (29 <sup>th</sup> )                    | 07/20/2022     | This authorization was not used in 2021  |
| j)                           | Grant of performance shares   | 1.2% of the share capital  | 05/20/2021 (18 <sup>th</sup> )                    | 11/20/2022     | 1,834,500 performance shares<br>(€14,676,000 par value) were granted<br>to 5,238 beneficiaries by decision of the<br>Board of Directors on 10/06/2021              |
|                              |   |  |   |                | 14,325 shares subject to presence conditions only (€114,600 par value) were granted to 63 beneficiaries by decision of the Board of Directors on 12/01/2021        |
| k)                           | Share capital increase by issuing shares and/or securities granting access to the share capital with cancellation of PSR, reserved for members of Group savings plans               | €32 million<br>(par value) (2)   | 05/20/2021 (19 <sup>th</sup> )                    | 11/20/2022     | 3,444,930 shares were issued pursuant to<br>this resolution in the context of the 2021<br>employee savings plan, representing a<br>par value amount of €27,559,440 |
| l)                           | Share capital increase by issuing shares and/or securities granting access to the share capital with cancellation of PSR, reserved for employees of certain non-French subsidiaries | €16 million<br>(par value) <sup>(2)</sup>  | 05/20/2021 (20 <sup>th</sup> )                    | 11/20/2022     | 161,757 shares were issued pursuant to<br>this resolution in the context of the 2021<br>employee savings plan, representing a<br>par value amount of €1,294,056    |

Recap of overall limits: a maximum par value amount of €540 million and a maximum issue amount of €9.3 billion for all issues with and without pre-emptive subscription rights; issues performed pursuant to j), k) and l) above are not included in these general limits.

Total share capital increases decided pursuant to k) and l) are subject to a maximum par value amount of €32 million.

Shares purchased in the course of 2021 but prior to the Ordinary Shareholders' Meeting of May 20, 2021 were acquired pursuant to the 20<sup>th</sup> resolution adopted by the Shareholder's Meeting of May 20, 2020.